Table 1 Summary of the demographics of the study cohort stratified by cancer histotype.
Cancer type | Total | |||||
|---|---|---|---|---|---|---|
HGSOC | ENOC | CCOC | MOC | LGSOC | ||
Age at diagnosis | ||||||
Mean | 60.4 | 55.4 | 56.6 | 55.2 | 53.9 | 58.5 |
SD | 11.2 | 12.4 | 11.7 | 15.2 | 13.1 | 12.1 |
Years followed | ||||||
Mean | 4.4 | 7.6 | 7.2 | 6.6 | 5.8 | 5.5 |
SD | 3.6 | 4.8 | 5.6 | 5.3 | 4.3 | 4.5 |
Delayed entry | ||||||
Mean | 0.4 | 0.6 | 0.5 | 0.6 | 0.6 | 0.5 |
Yes (%) | 31.1 | 33.9 | 31.8 | 36.3 | 30.7 | 32 |
Mean if yes | 1.2 | 1.9 | 1.7 | 1.8 | 1.9 | 1.4 |
SD if yes | 1.7 | 2.3 | 2.5 | 2.2 | 1.9 | 2 |
Number of cases (% per cancer subtype) | ||||||
Total | 3244 (100) | 840 (100) | 693 (100) | 405 (100) | 218 (100) | 5400 (100) |
Status at follow-up | ||||||
Data available | 3185 (100) | 810 (100) | 673 (100) | 396 (100) | 213 (100) | 5277 (100) |
Alive | 908 (29) | 550 (68) | 369 (55) | 238 (60) | 112 (53) | 2177 (41) |
Dead (disease) | 1619 (51) | 107 (13) | 140 (21) | 69 (17) | 71 (33) | 2006 (38) |
Dead (treatment) | 17 (1) | 4 (0) | 2 (0) | 0 (0) | 2 (1) | 25 (0) |
Dead (other) | 113 (4) | 40 (5) | 28 (4) | 22 (6) | 3 (1) | 206 (4) |
Dead (unknown) | 528 (17) | 109 (13) | 134 (20) | 67 (17) | 25 (12) | 863 (16) |
FIGO stage | ||||||
Data available | 2882 (100) | 667 (100) | 591 (100) | 324 (100) | 179 (100) | 4643 (100) |
Stage I | 236 (8) | 342 (51) | 295 (50) | 217 (67) | 45 (25) | 1135 (24) |
Stage II | 284 (10) | 189 (28) | 154 (26) | 36 (11) | 18 (10) | 681 (15) |
Stage III | 1994 (69) | 122 (18) | 130 (22) | 60 (19) | 104 (58) | 2410 (52) |
Stage IV | 368 (13) | 14 (2) | 12 (2) | 11 (3) | 12 (7) | 417 (9) |
Differentiation | ||||||
Data available | 2952 (100) | 792 (100) | 452 (100) | 381 (100) | 209 (100) | 4786 (100) |
Well | 1 (0) | 328 (41) | 16 (4) | 151 (40) | 176 (84) | 672 (14) |
Moderate | 376 (13) | 251 (32) | 57 (13) | 173 (45) | 3 (1) | 860 (18) |
Poor/none | 2575 (87) | 213 (27) | 379 (84) | 57 (15) | 30 (14) | 3254 (68) |
Residual tumour | ||||||
Data available | 2118 (100) | 462 (100) | 444 (100) | 237 (100) | 133 (100) | 3394 (100) |
Yes | 1176 (56) | 57 (12) | 91 (20) | 57 (24) | 62 (47) | 1443 (43) |
No | 942 (44) | 405 (88) | 353 (80) | 180 (76) | 71 (53) | 1951 (57) |
Cytoplasmic PTEN | ||||||
Data available | 2915 (100) | 775 (100) | 644 (100) | 360 (100) | 185 (100) | 4879 (100) |
Negative | 550 (19) | 273 (35) | 208 (32) | 69 (19) | 21 (11) | 1121 (23) |
Weak | 1455 (50) | 312 (40) | 312 (48) | 147 (41) | 90 (49) | 2316 (47) |
Positive | 733 (25) | 157 (20) | 107 (17) | 124 (34) | 64 (35) | 1185 (24) |
Heterogeneous | 177 (6) | 33 (4) | 17 (3) | 20 (6) | 10 (5) | 257 (5) |
Nuclear PTEN | ||||||
Data available | 2910 (100) | 774 (100) | 643 (100) | 359 (100) | 185 (100) | 4871 (100) |
0% | 1211 (42) | 483 (62) | 288 (45) | 171 (48) | 68 (37) | 2221 (46) |
[0, 10]% | 793 (27) | 141 (18) | 153 (24) | 77 (21) | 52 (28) | 1216 (25) |
[10, 50]% | 679 (23) | 114 (15) | 146 (23) | 72 (20) | 53 (29) | 1064 (22) |
[50, 100]% | 227 (8) | 36 (5) | 56 (9) | 39 (11) | 12 (6) | 370 (8) |
CD8 count | ||||||
Data available | 2893 (100) | 758 (100) | 627 (100) | 325 (100) | 154 (100) | 4757 (100) |
0 TIL | 479 (17) | 193 (25) | 295 (47) | 157 (48) | 40 (26) | 1164 (24) |
1–2 TIL | 481 (17) | 136 (18) | 135 (22) | 73 (22) | 40 (26) | 865 (18) |
3–19 TIL | 1278 (44) | 301 (40) | 119 (19) | 82 (25) | 63 (41) | 1843 (39) |
20+ TIL | 655 (23) | 128 (17) | 78 (12) | 13 (4) | 11 (7) | 885 (19) |
AR expression | ||||||
Data available | 2603 (100) | 662 (100) | 564 (100) | 317 (100) | 175 (100) | 4321 (100) |
Negative | 1669 (64) | 459 (69) | 532 (94) | 305 (96) | 109 (62) | 3074 (71) |
Positive | 934 (36) | 203 (31) | 32 (6) | 12 (4) | 66 (38) | 1247 (29) |
PR expression | ||||||
Data available | 1674 (100) | 590 (100) | 504 (100) | 267 (100) | 86 (100) | 3121 (100) |
Negative | 1068 (64) | 167 (28) | 469 (93) | 235 (88) | 34 (40) | 1973 (63) |
1–50% positive | 457 (27) | 111 (19) | 25 (5) | 18 (7) | 26 (30) | 637 (20) |
>50% positive | 149 (9) | 312 (53) | 10 (2) | 14 (5) | 26 (30) | 511 (16) |
ER expression | ||||||
Data available | 1258 (100) | 363 (100) | 336 (100) | 161 (100) | 66 (100) | 2184 (100) |
Negative | 289 (23) | 91 (25) | 283 (84) | 133 (83) | 9 (14) | 805 (37) |
1–50% positive | 277 (22) | 66 (18) | 21 (6) | 6 (4) | 13 (20) | 383 (18) |
>50% positive | 692 (55) | 206 (57) | 32 (10) | 22 (14) | 44 (67) | 996 (46) |
